Literature DB >> 23725118

Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India.

Syeda Zubeda1, Prabhakar Rao Kaipa, Noor Ahmad Shaik, Mohammed Khaliq Mohiuddin, Sireesha Vaidya, Boddana Pavani, Mukta Srinivasulu, Manolla Madhavi Latha, Qurratulain Hasan.   

Abstract

BACKGROUND: Categorizing breast tumors based on the ER, PR and HER/Neu 2 receptor status is necessary in order to predict outcome and assist in management of breast cancer. Herfe we assessed this question in South Indian patients.
MATERIALS AND METHODS: A total of 619 formalin fixed paraffin embedded breast tumor tissues were collected from pathology archives after receipt of ethical clearance. With the help of primary and secondary conjugated antibodies, expression status of ER, PR and HER2/neu was determined. All the experimental data were assessed for correlations with histopathological features of tumors and clinical presentation of the subjects.
RESULTS: In the present study, the ages ranged from 20-87 years with a mean of 50.0±12.q years, and majority of the tumors (84%) were of infiltrating duct cell carcinoma type. Assessment of ER, PR and Her-2/neu expression showed that 46% were triple negative. Interestingly, an inverse relation between ER, PR and HER-2/neu was apparent in 41.2% (p<0.0001) of the tumors, of which 24.5% (p<0.0001) were ER and PR co-negative but HER-2 positive.
CONCLUSIONS: ER and PR positive tumors are less common (i.e<30%) compared to HER-2/neu positive tumors (i.e>50%) in Indian breast cancer patients, underlining the need for effective diagnostic screening and specific therapeutic managements in order to improve the survival rate of patients in low resource countries such as India.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23725118     DOI: 10.7314/apjcp.2013.14.4.2231

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  17 in total

1.  Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways.

Authors:  Feng Qi; Wen-Xing Qin; Yuan-Sheng Zang
Journal:  Oncol Lett       Date:  2019-01-03       Impact factor: 2.967

2.  Patterns of Care of Breast Cancer Patients in a Rural Cancer Center in Western India.

Authors:  Bhagwan M Nene; Farida Selmouni; Manoj Lokhande; Sanjay J Hingmire; Richard Muwonge; Kasturi Jayant; Rengaswamy Sankaranarayanan
Journal:  Indian J Surg Oncol       Date:  2018-04-11

3.  Long non-coding RNA heart and neural crest derivatives expressed 2-antisense RNA 1 overexpression inhibits the proliferation of cancer cells by reducing RUNX2 expression in triple-negative breast cancer.

Authors:  Min Wei; Lei Liu; Zhiwei Wang
Journal:  Oncol Lett       Date:  2019-10-18       Impact factor: 2.967

Review 4.  Prevalence of Molecular Subtypes of Breast Cancer in India: a Systematic Review and Meta-analysis.

Authors:  Pavan Kumar Jonnada; Cherukuru Sushma; Madhuri Karyampudi; Anvesh Dharanikota
Journal:  Indian J Surg Oncol       Date:  2020-10-28

5.  Triple negative breast cancer: an Indian perspective.

Authors:  Murtaza Akhtar; Subhrajit Dasgupta; Murtuza Rangwala
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-08-14

6.  Expression and significance of DOK2 in colorectal cancer.

Authors:  Xianmei Wen; Muxiu Zhou; Yong Guo; Yanwu Zhu; Hong Li; Lu Zhang; Long Yu; Xiaocheng Wang; Xiaochun Peng
Journal:  Oncol Lett       Date:  2014-11-05       Impact factor: 2.967

7.  Co-expression and significance of Dok2 and Ras p21 protein activator 1 in breast cancer.

Authors:  Jiangrong Huang; Xiaochun Peng; Kun Zhang; Chunyan Li; Bo Su; Yanxiang Zhang; Wangui Yu
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

Review 8.  Improving accuracy of breast cancer biomarker testing in India.

Authors:  Tanuja Shet
Journal:  Indian J Med Res       Date:  2017-10       Impact factor: 2.375

Review 9.  Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis.

Authors:  Gurprataap S Sandhu; Sebhat Erqou; Heidi Patterson; Aju Mathew
Journal:  J Glob Oncol       Date:  2016-06-29

10.  Human epidermal growth factor receptor 2 and estrogen receptor status in respect to tumor characteristics in non-metastatic breast cancer.

Authors:  Hanifeh Mirtavoos-Mahyari; Adnan Khosravi; Zahra Esfahani-Monfared
Journal:  Tanaffos       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.